John Parkinson

A group of over 60 scientists participated in a communication to the federal agency to advocate for measuring these cells in COVID-19 vaccine trials.

The investigational vaccine's findings from their phase 1/2 clinical trial were reported at the World Vaccine Congress.

With an evolving understanding of T-cells in immunity and emerging SARS-Co-V2 strains, evaluating these vital protection cells can offer researchers insights into response and how to develop future therapies and vaccines.

The company says its first bivalent investigational vaccine, mRNA-1273.211, was efficacious against the Beta, Delta, and Omicron strains. They have identified another bivalent booster, mRNA-1273.214, which the company sees as its leading candidate for a fall 2022 scheduled dosing.

Masking requirements on public transportation was struck down by a federal judge late yesterday, which is leading to confusion for travelers today.

The InspectIR COVID-19 Breathalyzer test detects chemical compounds in breath samples associated with a SARS-CoV-2 infection.

The 36-fold increase in Omicron neutralizing titers in children between 5-11 years old is providing data for the companies to be able to file for an FDA EUA in this age group.

The investigational shots utilizing their mRNA technology platform are being studied in adults in the US.

A survey’s results show updating programs is largely dependent on resources and dedicated personnel.

A large veterans health administration study estimated antibiotic use during the last 6 months of life for patients under hospice or palliative care.

Although the numbers overall remain relatively low, the city states the rising cases as the reason for its decision.

April 10 is a day that commemorates a population group that is emerging in terms of increased incidence rates, and needs help with inherent challenges including medication adherence and understanding of the disease.

Company is working towards full Food and Drug Administration approval in the coming months.

As this is National Public Health Week, and COVID-19 is still top of mind for clinicians and public health officials, what is it going to take for it to become a secondary issue.

This year’s theme connects climate change and health.

New data coming from Israel shows the Pfizer-BioNTech COVID-19 vaccine did offer some protection initially, but waning immunity occurs rapidly.

Being displaced by war is causing a disruption in treatment and long-term health care for Ukrainians. And it is likely, the situation will become more dire as the country’s public infrastructure worsens.

The voluntary recall issued by the company last December was investigated by federal, state and local partners.

A recent study showed that 25% of mattresses within 4 hospitals required complete replacement, underlying a serious health risk that could lead to unnecessary infections.

The Food and Drug Administration (FDA) said the company is concerned about a limited number of jars that may contain a small fragment of stainless steel from a piece of manufacturing equipment.

The Center for Global Development is launching a new working group, which aims to address antimicrobial resistance by exploring how to improve incentives for pharmaceutical companies to develop new antimicrobials for low-income and middle-income countries (LMICs).

The new action by the federal agency now means the additional booster shot can be administered to people 50 years and older.

The federal agency is expected to provide the EUAs prior to their next VRBPAC meeting on April 6.

The company is developing a single combination vaccine to cover SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) as well as another candidate for endemic human coronaviruses.

This designation of the company’s respiratory syncytial virus (RSV) vaccine candidate, PF-06928316, will help to expedite its development and review.

Along with reporting positive data in the youngest pediatric population, the company is working with the Food and Drug Administration (FDA) for emergency use authorization of its vaccine in children 6 years to under 11 years as well as the 12-17 age groups.

A new virtual program aims to train clinicians and other providers on terminology and how to engage patients in effective dialogue and counseling.

The submission is for a fourth dose of its Spikevax (mRNA-1273) vaccine in adults 18 years of age and older.

The application is based on 2 Israeli studies for the additional shot for people 65 years and older.

This study comes just weeks after the company announced another HIV vaccine trial.